Instil Bio, Inc. (TIL) News
Filter TIL News Items
TIL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TIL News From Around the Web
Below are the latest news stories about INSTIL BIO INC that investors may wish to consider to help them evaluate TIL as an investment opportunity.
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of pat |
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual ConferencePresented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITIL-306 anticipated in 2024 DALLAS, June 26, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the |
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H’2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2023 financial results and provided a corporate |
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateInstil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its fourth quarter and full-year 2022 financial |
Private equity firms account for 39% of Instil Bio, Inc.'s (NASDAQ:TIL) ownership, while institutions account for 34%If you want to know who really controls Instil Bio, Inc. ( NASDAQ:TIL ), then you'll have to look at the makeup of its... |
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. SiteCompany anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL™ to its operations in Manchester, U.K. Instil to extend previously announced reduction-in-force to reduce US headcount DALLAS, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing next- |
Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal CancersInstil Bio Inc (NASDAQ: TIL) has resumed its Phase 1 clinical trial of ITIL-306 for non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC). With the resumption of the ITIL-306 Phase 1 study, the company plans to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023. The trial was resumed after implementing additional quality safeguards designed to further protect the manufacturing process from potential c |
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal CancerPhase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company expects cash runway into 2025, excluding potential financing or other monetization of Tarzana manufacturing site DALLAS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focus |
Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)Instil Bio, Inc. (TIL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |